Treatment Information

Back

Melanoma treatment details. Immunotherapy.

Churchill Hospital, Oxford, United Kingdom.

Survival: monthsCountry:United Kingdom
Toxiciy Grade:4City/State/Province:Oxford
Treatments:ImmunotherapyHospital:Churchill Hospital
Drugs:Journal:Link
Date:Jan 2014

Description:

Patients:
This phase 2 study involved 96 melanoma patients with a median age of 53 years and 47.9% male.

Treatment:
Patients received immunotherapy with interferon-alpha 2b (IFN-a-2b), which stimulates the immune system to attack cancer cells.

Toxicities:
The most severe toxicities were of grade 4 and included neutropenia, liver toxicity, and fatigue. Grade 1-2 vomiting and nausea were also reported.

Results:
The median overall survival was 41.5 months.

Support:
Some of the study’s authors have advisory and/or financial relationships with several pharmaceutical companies.

Correspondence: Dr. Mark R. Middleton; email: Mark.Middleton@oncology.ox.ac.uk



Back